Zoptarelin Doxorubicin

Also called: AEZS-108; AEZS 108; AN-152; Zoptarelin doxorubicin acetate

What it is

An LHRH agonist-doxorubicin conjugate (AEZS-108); phase 2 activity in endometrial, ovarian and prostate cancer; phase 3 not superior to doxorubicin.

Approval status

Discontinued. Never approved. openFDA's Drugs@FDA index returns no record (searched October 3, 2026). The phase 3 endometrial cancer trial (NCT01767155, 511 enrolled, completed) found it not superior to free doxorubicin (PubMed 33535622).

Dosing, as printed in the page's Recommended Dosing box

Used in human trials

No manufacturer dose exists for this use: these are amounts given in published trials, not recommendations.

Protocol and source	Dose	Frequency	Duration	Route
Phase 2: platinum-resistant ovarian cancer **[Human study]** PMID 24713545	267 mg/m²	Every 3 weeks	Until progression	Intravenous infusion
Phase 2: castration- and taxane-resistant prostate cancer **[Human study]** PMID 28668277	210 mg/m²	Every 3 weeks	Until progression	Intravenous infusion

Educational information, not medical advice. Each dose above is tagged with its source: an approved label, a published human study, animal data, or amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for "research use only" are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.

Key human evidence

The first 3 of the 5 human studies carded on the page (14 study cards in all):

- **Phase 2 in endometrial cancer** (Human, 2014). In 43 eligible women with LHRH receptor-positive advanced or recurrent endometrial cancer, 2 (5%) had complete and 8 (18%) partial remissions, 44% stable disease; median time to progression 7 months and overall survival 15 months; grade 3-4 neutropenia 12%, leucopenia 9%. **PMID 24418927**
- **Phase 2 in platinum-resistant ovarian cancer** (Human, 2014). Of 42 women given 267 mg/m2 every 3 weeks, 6 (14.3%) had partial responses and 16 (38%) stable disease; median time to progression 12 weeks and overall survival 53 weeks; 93% of screened tumours expressed LHRH receptors. **PMID 24713545**
- **Phase 2 in resistant prostate cancer** (Human, 2017). In 25 men with castration- and taxane-resistant prostate cancer given 210 mg/m2 every 3 weeks, 52% were progression-free at 12 weeks without limiting toxicity; median PFS 3.8 months and OS 6.0 months; pain improved in 59%. **PMID 28668277**

Interactions

A PubMed search for interaction studies of this compound with any drug (October 3, 2026, 5 records) found none in people. That is not evidence that it is safe to combine with anything.

Side effects and cautions

Reported side effects	Contraindications and cautions
• Neutropenia (grade 3-4 in 12% in endometrial cancer) • Leucopenia (grade 3-4 in 9%)	• Prior anthracycline therapy (endometrial phase 2)

Five questions to ask

1. Zoptarelin Doxorubicin is listed here as "Discontinued". What does the evidence on this sheet mean for someone in my situation, and is there an approved treatment I should consider instead?
2. Here are the medicines and supplements I take. Do any of them interact with Zoptarelin Doxorubicin? This sheet records none published, which does not mean none exist.
3. Which side effects should make me stop and call you, for example neutropenia?
4. Do any of the cautions on this sheet apply to me, such as: Prior anthracycline therapy?
5. What should we check before I start and while I am on it (blood tests, blood pressure, weight), and how often?

Grey Peptides is a vendor-neutral encyclopedia: it sells nothing and names no seller. This sheet is educational, not medical advice, and is not a prescription.